期刊文献+

抗自身免疫性疾病主要生物制剂的研究进展 被引量:1

Main biologics for anti-autoimmune disease:research advances
下载PDF
导出
摘要 免疫系统有助于人类排斥或清除细菌、病毒、寄生虫等外来入侵,但当机体的某些组织成分或免疫系统自身出现异常时,它就不能有效地分辨敌我,甚至攻击自身组织引起一些临床症状,形成自身免疫性疾病。全世界有近5%的人口饱受各种自身免疫病的困扰,目前比较常用的治疗方案除了控制自身抗原的形成原因如感染、劳累等外,主要采用有免疫调节功能的生物制剂来阻断病理性自身免疫应答或者建立新的正确的免疫应答。近年来,治疗自身免疫病的新型生物制剂层出不穷,本文综述了目前常用抗自身免疫性疾病的生物制剂及其研究进展。 Immune system is a security guard to help human body repel or remove bacteria, viruses, parasites and other fore-ign invaders .But when some tissue components or the immune system itself become abnormal, it can not distinguish friend from foe accurately and may attack our own tissue then cause some clinical symptoms, leading to autoimmune diseases. Nearly 5 % of the world's population suffer from various autoimmune diseases. By now in addition to control the formation of autoantigens such as infection,tiredness, the main biologics used in clinic are immunoregulators to block pathological autoimmune response and then to create a new proper immune response. Recently, new biologics to treat autoimmune disease come into being one after another, and this article gives a brief overview about research progress in anti-autoimmune disease biologics.
出处 《国际药学研究杂志》 CAS CSCD 2014年第4期424-428,共5页 Journal of International Pharmaceutical Research
关键词 自身免疫性疾病 生物制剂 免疫抑制 autoimmune disease biologics immunosuppression
  • 相关文献

参考文献26

  • 1van Vollenhoven R,Kinnman N,Vincent E,et al.Atacicept inpatients with rheumatoid arthritis and an inadequate response tomethotrexate:results of a phase II,randomized,placebcK^on-trolled trial[j].Arthritis Rheum,2011,63(7):1782-1792.
  • 2Navarra SV,Guzm a n RM,Gallacher AE,et al.Kfficacy andsafety of helimumab in patients with active systemic lupuserythematosus:a randomised,placebo-controlled,phase 3 trial [ J ].Lancet,2011,377(9767):721-731.
  • 3Sanz I.Connective tissue diseases:targeting B cells in SLE:goodnews at last![J].Nat Rev Rheumat,2011,7(5):255-256.
  • 4Shaw M,Del Giudice J,Trapp R.The safety,pharmacokinetics(PK)and pharmacodynamic(PD)effects of repeated doses ofBR3-Fc in patients with rheumatoid arthritis(RA)[j].Arthritis Rheum,2007,56:S568-S569.
  • 5Guadagnoli M,Kimberley FC,Phan U,et al.Development andcharacterization of APRIL antagonistic monoclonal antibodies fortreatment of B-cell lymphomas[j].Blood,2011,117(25):6856-6865.
  • 6Toussirot,Houvenagel,Goeh V,et al.Development ofinflammatory howel disease during anti-TNF-a therapy forinflammatory rheumatic disease.A nationwide series [J].Joint Bone Spine,2012,79(5):457-463.
  • 7Burmester GR,Matucri-Cerinic M,Mariette X,et al.Safety andeffectiveness of adalimumah in patients with rheumatoid arthritisover 5 years of therapy in a phase 3h and subsequent postmarketingobservational study [j].Arthritis Res Ther,2014,16(1):R24.
  • 8Shale M,Seow C,Coffin C,et al.Review article:chronic viralinfection in the anti-tumour necrosis factor therapy era in infla-mmatory howel disease[j].Alim Pharm Ther,2010,31(1):20-34.
  • 9Hsu H C,Yang P,Wang J,et al.Interleukin 17-producing Thelper cells and interleukin 17 orchestrate autoreaotive germinalcenter development in autoimmune BXD2 mice[ J ].Nat Immunol,2008,9(2):166-175.
  • 10Dolff S,Abdulahad WH,Bijl M,et al.Regulators of B-cell activityin SLE:a better target for treatment than B-cell depletion [j ].2009,18(7):575-580.

同被引文献18

引证文献1

二级引证文献1

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部